TCL Archive FDA approval of two colon cancer therapies triggers discussion among researchers, clinicians about best treatment and clinical trial designs. CMS reimbursement pending; costs to U.S. of the new drugs could be billions per year, but some predict dramatic increases in survival. March 5, 2004
TCL Archive Ethicists dispute von Eschenbach’s claim that his NCI-FDA conflicts are managed. NCI-FDA chief appears to cite Klausner-era “in-box rule.” December 16, 2005
